SUBSCRIBE
SUBSCRIBE

Ventracor Limited Release: Preparing For EU Market Launch

June 19, 2006 | 
1 min read

Ventracor Limited (ASX: VCR) today announced the first patient has been implanted with the VentrAssist in a new study designed to build on clinical momentum from the CE Mark Trial and prepare for European market launch.

Australia
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Drug Development
Kazia’s Star Asset Suffers Surprise Letdown in Global Glioblastoma Study
August 2, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Sapience, Intensity, Kazia and Transcenta Tout Early Success at ASCO
June 3, 2022
 · 
3 min read
 · 
Vanessa Doctor, RN
Drug Development
Inaugural Patient Injected with Cancer-Killing Oncolytic Virus
May 24, 2022
 · 
2 min read
 · 
Jazmine Colatriano M.S.